retatrutide weight loss clinical trial retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide: FDA approval time, trial

doi: 10.1038/s41586-025-09588-6 238 MichaudM.BalardyL.MoulisG.GaudinC.PeyrotC.VellasB.et al

Here are the three main reasons: GLP-1s Help With Conditions That Disproportionately Affect Bipolar Disorder Theres a high percentage of people living with bipolar disorder who also experience metabolic changes in their body that put them at risk for things like heart disease and type 2 diabetes, says Vijay Gorrepati, MD, psychiatrist at UT Health Austins Bipolar Disorder Center in Texas, which is associated with Dell Medical School

Beginner protocol: 1 mg weekly, administered as a single injection or split into two 500mcg doses

Thats why we focus on all aspects of your health at our weight loss clinic, because its not just about the number on the scale